No. patients | 58 | 85 | 92 | 122 | 143 | 157 | 224 | 255 | |
DMARD^ | | | | | | | | | |
Baseline | 40/44 (90.9) | 68/72 (94.4) | 65/67 (97.0) | 90/97 (92.8) | 126/134 (94.0) | 146/151 (96.7) | 156/162 (96.3) | 163/165 (98.8) | 0.170 |
6 mos | 42/42 (100) | 49/56 (87.5) | 59/59 (100) | 87/92 (94.6) | 104/111 (93.7) | 123/126 (97.6) | 130/135 (96.3) | 157/159 (98.7) | 0.002 |
MTX^ | | | | | | | | | |
Baseline | 38/44 (86.4) | 37/72 (51.4) | 53/67 (79.1) | 72/97 (74.2) | 107/134 (79.9) | 134/151 (88.7) | 108/162 (66.7) | 136/165 (82.4) | 0.001 |
6 mos | 41/42 (97.6) | 33/56 (58.9) | 47/59 (79.7) | 71/92 (77.2) | 93/111 (83.8) | 114/126 (90.5) | 97/135 (71.9) | 137/159 (86.2) | 0.001 |
MTX, SC^ | | | | | | | | | |
Baseline | 3/44 (6.8) | 4/72 (5.6) | 8/67 (11.9) | 7/97 (7.2) | 7/134 (5.2) | 43/151 (28.5) | 101/162 (62.3) | 62/165 (37.6) | 0.001 |
6 mos | 4/42 (9.5) | 11/56 (19.6) | 10/59 (16.9) | 17/92 (18.5) | 18/111 (16.2) | 42/126 (33.3) | 92/135 (68.1) | 88/159 (55.3) | 0.001 |
Biologic^ | | | | | | | | | |
Baseline | 9/44 (20.5) | 3/72 (4.2) | — | 1/97 (1.0) | 6/134 (4.5) | 1/151 (0.7) | — | 4/165 (2.4) | 0.001 |
6 mos | 20/42 (47.6) | 6/56 (10.7) | 2/59 (3.4) | 7/92 (7.6) | 5/111 (4.5) | 11/126 (8.7) | — | 25/159 (15.7) | 0.001 |
At least 2 DMARD^ | | | | | | | | | |
Baseline | 12/44 (27.3) | 32/72 (44.4) | 22/67 (32.8) | 34/97 (35.1) | 104/134 (77.6) | 49/151 (32.5) | 30/162 (18.5) | 92/165 (55.8) | 0.001 |
6 mos | 17/42 (40.5) | 30/56 (53.6) | 40/59 (67.8) | 33/92 (35.9) | 88/111 (79.3) | 66/126 (52.4) | 33/135 (24.4) | 101/159 (63.5) | 0.001 |
Medication ever changed* | 28/45 (62.2) | 34/68 (50.0) | 41/66 (62.1) | 36/101 (35.6) | 44/128 (34.4) | 65/143 (45.5) | 19/158 (12.0) | 79/166 (47.6) | 0.001 |
Medication ever increased* | 26/45 (57.8) | 24/68 (35.3) | 40/66 (60.6) | 26/101 (25.7) | 31/128 (24.2) | 57/143 (39.9) | 14/158 (8.9) | 67/166 (40.4) | 0.001 |